2 independently checked trend briefs about this subject, newest first.
headlinez.news detected 2 source-qualified news clusters connected to Deramiocel between July 27, 2026 and July 27, 2026. They span 1 newsroom category and average 8.0 independent sources per brief.
This hub includes only briefs supported by at least four sources and passed by the site's verification gate. Raw or weak detections may exist but are excluded here. Topic matching is based on the entities and themes recorded with each brief; open a card to inspect its source links, publication time, verification label and velocity history. Read the methodology and editorial policy for the full rules.
Capricor Therapeutics faces market volatility and legal investigations following the release of FDA staff documents regarding its therapy, Deramiocel.
FDA staff have raised significant concerns regarding the efficacy data for Capricor Therapeutics' experimental heart disease therapy for Duchenne patients.